Neumora Therapeutics (NMRA) President awarded 1.2M share stock option grant

Q: Who received the stock option grant reported in Neumora Therapeutics (NMRA) Form 4?

The Form 4 reports that Joshua Pinto , President of Neumora Therapeutics, Inc. , received the stock option grant.

Q: What is the size of Joshua Pinto’s stock option grant at Neumora Therapeutics (NMRA)?

The grant is a stock option to purchase 1,200,000 shares of Neumora Therapeutics common stock.

Q: How do the stock options granted to Joshua Pinto at Neumora Therapeutics vest?

25% of the option shares vest on the first anniversary of January 8, 2026, and the remaining shares vest monthly in equal installments so that all shares are vested on the fourth anniversary of that date.

Q: Is the stock option grant to Joshua Pinto reported as directly owned?

Yes. The Form 4 shows 1,200,000 derivative securities beneficially owned following the transaction with ownership form reported as Direct (D) .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. reported a new equity award for President Joshua PintoJanuary 8, 2026, he was granted an option to purchase 1,200,000 shares of common stock at an exercise price of $2.33 per share. According to the vesting terms, 25% of the shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested on the fourth anniversary of the vesting commencement date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pinto Joshua

Role President

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,200,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 1,200,000 shares (Direct)

Footnotes (1)

[object Object]

Form 4 Insider Transactions: What Each Field Means →

01/09/2026 - 04:18 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pinto Joshua

(Last)

(First)

(Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL WAY, SUITE 1

(Street)

WATERTOWN

02472

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.33	01/08/2026		A		1,200,000		⁽¹⁾	01/08/2036	Common Stock	1,200,000	$0	1,200,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

	/s/ Michael Milligan, as Attorney-in-Fact for Joshua Pinto	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who received the stock option grant reported in Neumora Therapeutics (NMRA) Form 4?

The Form 4 reports that Joshua Pinto, President of Neumora Therapeutics, Inc., received the stock option grant.

What is the size of Joshua Pinto’s stock option grant at Neumora Therapeutics (NMRA)?

The grant is a stock option to purchase 1,200,000 shares of Neumora Therapeutics common stock.

What is the exercise price of the stock options granted to Neumora Therapeutics President Joshua Pinto?

The stock option has an exercise price of $2.33 per share.

How do the stock options granted to Joshua Pinto at Neumora Therapeutics vest?

25% of the option shares vest on the first anniversary of January 8, 2026, and the remaining shares vest monthly in equal installments so that all shares are vested on the fourth anniversary of that date.

When was the stock option grant to Neumora Therapeutics President Joshua Pinto made effective?

The stock option grant was made effective on January 8, 2026, as reported in the Form 4.

Is the stock option grant to Joshua Pinto reported as directly owned?

Yes. The Form 4 shows 1,200,000 derivative securities beneficially owned following the transaction with ownership form reported as Direct (D).